• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低浓度/剂量的他克莫司会增加急性钙调神经磷酸酶抑制剂诱导的肾毒性发生风险。

A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity.

作者信息

Thölking Gerold, Schütte-Nütgen Katharina, Schmitz Julia, Rovas Alexandros, Dahmen Maximilian, Bautz Joachim, Jehn Ulrich, Pavenstädt Hermann, Heitplatz Barbara, Van Marck Veerle, Suwelack Barbara, Reuter Stefan

机构信息

Department of Medicine D, Division of General Internal Medicine, Nephrology and Rheumatology, University Hospital of Münster, 48149 Münster, Germany.

Department of Internal Medicine and Nephrology, University Hospital of Münster, Marienhospital Steinfurt, 48565 Steinfurt, Germany.

出版信息

J Clin Med. 2019 Oct 2;8(10):1586. doi: 10.3390/jcm8101586.

DOI:10.3390/jcm8101586
PMID:31581670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6832469/
Abstract

Fast tacrolimus metabolism is linked to inferior outcomes such as rejection and lower renal function after kidney transplantation. Renal calcineurin-inhibitor toxicity is a common adverse effect of tacrolimus therapy. The present contribution hypothesized that tacrolimus-induced nephrotoxicity is related to a low concentration/dose (C/D) ratio. We analyzed renal tubular epithelial cell cultures and 55 consecutive kidney transplant biopsy samples with tacrolimus-induced toxicity, the C/D ratio, C0, C2, and C4 Tac levels, pulse wave velocity analyses, and sublingual endothelial glycocalyx dimensions in the selected kidney transplant patients. A low C/D ratio (C/D ratio < 1.05 ng/mL×1/mg) was linked with higher C2 tacrolimus blood concentrations (19.2 ± 8.7 µg/L vs. 12.2 ± 5.2 µg/L respectively; = 0.001) and higher degrees of nephrotoxicity despite comparable trough levels (6.3 ± 2.4 µg/L vs. 6.6 ± 2.2 µg/L respectively; = 0.669). However, the tacrolimus metabolism rate did not affect the pulse wave velocity or glycocalyx in patients. In renal tubular epithelial cells exposed to tacrolimus according to a fast metabolism pharmacokinetic profile it led to reduced viability and increased Fn14 expression. We conclude from our data that the C/D ratio may be an appropriate tool for identifying patients at risk of developing calcineurin-inhibitor toxicity.

摘要

他克莫司代谢过快与肾移植后诸如排斥反应和肾功能降低等不良后果相关。肾钙调神经磷酸酶抑制剂毒性是他克莫司治疗的常见不良反应。本研究推测,他克莫司诱导的肾毒性与低浓度/剂量(C/D)比值有关。我们分析了肾小管上皮细胞培养物以及55例连续的有他克莫司诱导毒性的肾移植活检样本,测定了所选肾移植患者的C/D比值、C0、C2和C4他克莫司水平、脉搏波速度分析以及舌下内皮糖萼尺寸。低C/D比值(C/D比值<1.05 ng/mL×1/mg)与较高的他克莫司血药浓度C2相关(分别为19.2±8.7 μg/L和12.2±5.2 μg/L;P = 0.001),尽管谷浓度相当(分别为6.3±2.4 μg/L和6.6±2.2 μg/L;P = 0.669),但肾毒性程度更高。然而,他克莫司代谢率并未影响患者的脉搏波速度或糖萼。在根据快速代谢药代动力学特征暴露于他克莫司中的肾小管上皮细胞中,它导致细胞活力降低和Fn14表达增加。我们从数据中得出结论,C/D比值可能是识别有发生钙调神经磷酸酶抑制剂毒性风险患者的合适工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/c49afe840fe0/jcm-08-01586-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/139fed243f42/jcm-08-01586-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/e614bc68ed62/jcm-08-01586-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/39acdd2c9369/jcm-08-01586-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/4d5a29a12e48/jcm-08-01586-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/9ab908d5fa60/jcm-08-01586-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/c49afe840fe0/jcm-08-01586-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/139fed243f42/jcm-08-01586-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/e614bc68ed62/jcm-08-01586-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/39acdd2c9369/jcm-08-01586-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/4d5a29a12e48/jcm-08-01586-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/9ab908d5fa60/jcm-08-01586-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/684a/6832469/c49afe840fe0/jcm-08-01586-g006.jpg

相似文献

1
A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced Nephrotoxicity.低浓度/剂量的他克莫司会增加急性钙调神经磷酸酶抑制剂诱导的肾毒性发生风险。
J Clin Med. 2019 Oct 2;8(10):1586. doi: 10.3390/jcm8101586.
2
A Low Tacrolimus Concentration-to-Dose Ratio Increases Calcineurin Inhibitor Nephrotoxicity and Cytomegalovirus Infection Risks in Kidney Transplant Recipients: A Single-Center Study in Japan.低他克莫司浓度-剂量比增加肾移植受者钙调神经磷酸酶抑制剂肾毒性和巨细胞病毒感染风险:日本一项单中心研究
Transplant Proc. 2023 Jan-Feb;55(1):109-115. doi: 10.1016/j.transproceed.2022.12.004. Epub 2023 Jan 7.
3
Influence of tacrolimus metabolism rate on renal function after solid organ transplantation.他克莫司代谢率对实体器官移植后肾功能的影响。
World J Transplant. 2017 Feb 24;7(1):26-33. doi: 10.5500/wjt.v7.i1.26.
4
Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.关注肾移植中的mTOR抑制剂和他克莫司:药代动力学、暴露-反应关系及临床结局。
Transpl Immunol. 2014 Jun;31(1):22-32. doi: 10.1016/j.trim.2014.05.002. Epub 2014 May 24.
5
Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients.他克莫司药代动力学的高个体内和个体间变异性以及他克莫司快速代谢对实体器官移植受者结局的影响
J Clin Med. 2020 Jul 11;9(7):2193. doi: 10.3390/jcm9072193.
6
Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.从纵向组织学角度看钙调神经磷酸酶抑制剂肾毒性:环孢素时代与他克莫司时代的比较
Transplantation. 2016 Aug;100(8):1723-31. doi: 10.1097/TP.0000000000001243.
7
Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers After Renal Transplantation.肾移植后,转换为依维莫司对他克莫司代谢快和慢的患者有益且安全。
J Clin Med. 2020 Jan 23;9(2):328. doi: 10.3390/jcm9020328.
8
Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation.他克莫司浓度/剂量比值与肝移植术后肾功能相关。
Ann Transplant. 2016 Mar 22;21:167-79. doi: 10.12659/aot.895898.
9
The Clinical Impact of the C/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients.C/D 比值和 CYP3A5 基因分型对接受他克莫司治疗的肾移植受者预后的临床影响
Front Pharmacol. 2020 Jul 31;11:1142. doi: 10.3389/fphar.2020.01142. eCollection 2020.
10
Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.零时活检中的动脉硬化是他克莫司诱导的慢性肾毒性的一个危险因素。
Nephrology (Carlton). 2015 Jul;20 Suppl 2:51-7. doi: 10.1111/nep.12461.

引用本文的文献

1
Early Determination of Tacrolimus Concentration-Dose Ratio Identifies Risk of Allograft Loss in Kidney Transplantation.早期测定他克莫司浓度-剂量比可识别肾移植中移植肾丢失的风险。
Kidney Int Rep. 2025 Feb 25;10(5):1428-1440. doi: 10.1016/j.ekir.2025.02.014. eCollection 2025 May.
2
Optimization of the Tacrolimus Concentration-to-Dose Ratio Cut-Off Value to Define Metabolism Groups.优化他克莫司浓度与剂量比值的截断值以定义代谢组。
J Clin Med. 2025 Apr 8;14(8):2542. doi: 10.3390/jcm14082542.
3
The tacrolimus concentration-to-dose ratio is associated with kidney function in heart transplant recipients.

本文引用的文献

1
Tacrolimus: Influence of the Posttransplant Concentration/Dose Ratio on Kidney Graft Function in a Two-Year Follow-Up.他克莫司:移植后浓度/剂量比在两年随访期间对肾脏移植物功能的影响。
Kidney Blood Press Res. 2019;44(5):1075-1088. doi: 10.1159/000502290. Epub 2019 Sep 13.
2
The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.TOMATO 研究(肾移植中环孢素的代谢):浓度-剂量比对无失功移植物存活率的影响。
Transplantation. 2020 Jun;104(6):1263-1271. doi: 10.1097/TP.0000000000002920.
3
Dose-adjusted and dose/kg-adjusted concentrations of mycophenolic acid precursors reflect metabolic ratios of their metabolites in contrast with tacrolimus and cyclosporine.
他克莫司浓度与剂量之比与心脏移植受者的肾功能相关。
Br J Clin Pharmacol. 2025 Aug;91(8):2363-2377. doi: 10.1002/bcp.70041. Epub 2025 Mar 19.
4
Tacrolimus-why pharmacokinetics matter in the clinic.他克莫司——为何药代动力学在临床中至关重要。
Front Transplant. 2023 Aug 21;2:1160752. doi: 10.3389/frtra.2023.1160752. eCollection 2023.
5
The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.每日两次使用缓释他克莫司可能对特定肾移植受者有益:一例病例报告。
Front Med (Lausanne). 2024 Jun 26;11:1336035. doi: 10.3389/fmed.2024.1336035. eCollection 2024.
6
Therapeutic drug monitoring of tacrolimus after kidney transplantation: trough concentration or area under curve-based monitoring?肾移植后他克莫司的治疗药物监测:谷浓度监测还是基于曲线下面积的监测?
Br J Clin Pharmacol. 2025 Jun;91(6):1600-1606. doi: 10.1111/bcp.16098. Epub 2024 Jun 6.
7
Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.从即时或延长释放改为每日一次的延长释放他克莫司(LCPT)对稳定肾移植受者震颤的影响:观察性 ELIT 研究。
Transpl Int. 2024 Apr 17;37:11571. doi: 10.3389/ti.2024.11571. eCollection 2024.
8
Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus.基于生理的药代动力学模型结合反向剂量法研究他克莫司的肾毒性耐受剂量。
Arch Toxicol. 2023 Oct;97(10):2659-2673. doi: 10.1007/s00204-023-03576-3. Epub 2023 Aug 12.
9
EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients.EnGraft 研究:一项多中心、开放性标签、随机、双臂、优效性研究方案,旨在评估肝移植受者中 Envarsus®与 Advagraf™的生物利用度和实用性。
Trials. 2023 May 11;24(1):325. doi: 10.1186/s13063-023-07344-7.
10
Does the Tacrolimus Trough Level Adequately Predict Drug Exposure in Patients Requiring a High Tacrolimus Dose?他克莫司谷浓度能否充分预测需要高剂量他克莫司治疗的患者的药物暴露情况?
Transplant Direct. 2023 Mar 29;9(4):e1439. doi: 10.1097/TXD.0000000000001439. eCollection 2023 Apr.
调整剂量和按体重调整剂量的麦考酚酸前体浓度反映了其代谢物与他克莫司和环孢素的代谢比值。
Biosci Rep. 2019 Sep 13;39(9). doi: 10.1042/BSR20182031. Print 2019 Sep 30.
4
Tacrolimus exposure after liver transplantation for alcohol-related liver disease: Impact on complications.酒精性肝病肝移植后他克莫司暴露:对并发症的影响。
Transpl Immunol. 2019 Oct;56:101227. doi: 10.1016/j.trim.2019.101227. Epub 2019 Jul 24.
5
Tacrolimus Concentration-to-Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes.肾移植受者他克莫司浓度-剂量比值与临床结局的关系。
Pharmacotherapy. 2019 Aug;39(8):827-836. doi: 10.1002/phar.2300. Epub 2019 Jul 18.
6
Fast Tac Metabolizers at Risk ⁻ It is Time for a C/D Ratio Calculation.快代谢型患者面临风险——是时候计算C/D比值了。
J Clin Med. 2019 Apr 28;8(5):587. doi: 10.3390/jcm8050587.
7
Current assessment of pulse wave velocity: comprehensive review of validation studies.目前的脉搏波速度评估:验证研究的综合综述。
J Hypertens. 2019 Aug;37(8):1547-1557. doi: 10.1097/HJH.0000000000002081.
8
High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study.高他克莫司清除率 - 移植肾发生间质纤维化和肾小管萎缩的危险因素:一项回顾性单中心队列研究。
Transpl Int. 2019 Mar;32(3):257-269. doi: 10.1111/tri.13356. Epub 2018 Oct 15.
9
Getting a Notch closer to renal dysfunction: activated Notch suppresses expression of the adaptor protein Disabled-2 in tubular epithelial cells. Notch 途径更近一步:激活的 Notch 抑制管状上皮细胞中衔接蛋白 Disabled-2 的表达。
FASEB J. 2019 Jan;33(1):821-832. doi: 10.1096/fj.201800392RR. Epub 2018 Jul 27.
10
Association of impaired endothelial glycocalyx with arterial stiffness, coronary microcirculatory dysfunction, and abnormal myocardial deformation in untreated hypertensives.未经治疗的高血压患者中,内皮糖萼功能障碍与动脉僵硬度、冠状动脉微循环功能障碍和心肌变形异常相关。
J Clin Hypertens (Greenwich). 2018 Apr;20(4):672-679. doi: 10.1111/jch.13236. Epub 2018 Mar 2.